Neurogene reaffirms Embolden data for 2H 2027, cash runway into Q1 2029
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
3 stories
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
Kodiak said both Phase 3 DAYBREAK arms hit their primary endpoints, with a Zenkuda BLA planned by year end and KSI-101 topline data due in December.
SEC filing (2)
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (10)